Additional Effects of Ladder Drills and Jump Training in Taekwondo Players

January 8, 2026 updated by: Riphah International University

Additional Effects of Ladder Drills and Jump Training on Agility, Core Stability and Balance of Taekwondo Players

A Randomized controlled trial will be conducted with sample size of 40 players divided into two groups of 20, 20 players in each. Players will undergo 18 training sessions in six weeks, and each week has three training sessions. Each session, including a 10-minute warm-up and a 10-minute cool down, with 60 minutes in duration. The training will start with low intensity for the first two weeks, then progress to moderate intensity for the next two weeks, and finally reach high intensity, to the individual's ability and physical endurance.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Taekwondo is a dynamic martial art that requires skill in speed, strength, flexibility, and coordination. It includes a variety of powerful techniques, such as kicks, punches, and defensive moves. For athletes to perform at their best and reduce the risk of injury, it is essential to develop flexibility, balance, and core strength. However, traditional Taekwondo training often emphasizes agility, instead of core stability and balance. The most basic drill involves jumping with one foot into each box of the ladder in motion forward and then the other foot in a quick manner. Jump training, especially plyometric training, is concerned with training the body to produce explosive force and speed, essential qualities in a taekwondo performer. To address this issue, the current study aims to explore the added benefits of combining ladder drills and jump training into a regular Taekwondo training program. This is a single-blinded, randomized controlled trial and will involve male Taekwondo athletes aged 18 to 25. Participants will be randomly assigned into two groups: Group A will receive standard Taekwondo training with ladder and jump drills, while Group B will focus on standard Taekwondo training only. This will be a 6-week training program consisting of a total of 18 sessions held 3 times a week. Each 60-minute session will include a 10-minute warm-up, 40 minutes of ladder drills and jump training, and a 10-minute cool-down phase. Data will be collected from athletes affiliated with the Pakistan Sports Board Lahore, focusing on three key variables: agility, core strength, and balance. These variables will be measured using standardized tests: the T-Test for agility, the Plank Test for core stability, and the Star Excursion Balance Test for balance. Assessments will be conducted before and after the training program to find changes in these physical characteristics. The results of this study will aim to assist coaches and trainers in enhancing Taekwondo performance while also focusing on injury prevention.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab Province
      • Lahore, Punjab Province, Pakistan
        • Pakistan Sports Board coaching center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Male Players
  • Age 18-25 years
  • Body mass index (BMI) between 20 and 30 kg/m2
  • Participants with 1 year experience in Taekwondo

Exclusion Criteria:

  • Players with any neurological disease that impairs balance or coordinated movement
  • Participants will be involved in weight loss during the period of this study
  • Current Musculoskeletal Injury
  • Using any performance-enhancing drugs or supplements
  • History of Lower Limb Injury or Surgery in the Past Year

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Group A
Intervention Group (Ladder Drills + Jump Training) The intervention plan consists of two main parts: Ladder Training and Jump Training, each lasting 20 minutes.
Other: Ladder drills
The intervention plan consists ladder drills lasting 20 minutes.
Other: Jump training
The intervention plan consists jump training lasting 20 minutes.
Experimental: Group B
Control Group (Conventional Training) The control group plan will include 20 minutes of dynamic stretching and 20 minutes of aerobic training.
Other: Jump training
The intervention plan consists jump training lasting 20 minutes.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
T-Test for Agility
Time Frame: 6 weeks
The T-Test takes 1-2 minutes per trial, and therefore 5-6 minutes for 2-3 trials. A typical arrangement of cones has 5m with the top of the Τ letter and 2.5m between them horizontally, while they are 9 to 12 inches high generally. Runners race ahead, make side-to-side movements to the left and right, then run backward to the starting line; the best agility scores are the shortest.
6 weeks
Core Stability Test
Time Frame: 6 weeks
The Core Stability Test may take anywhere between 1 and 3 minutes per trial. Superior core stability is demonstrated in exercising athletes who undertake as long as possible for the forearm plank position.
6 weeks
Star Excursion Balance Test (SEBT)
Time Frame: 6 weeks
The SEBT will measure dynamic balance by 2 to 3 minutes for each trial. Athletes stand on one leg and reach as far as possible in eight directions: forward, backward, inward, outward, forward-inward, forward-outward, backward-inward, and backward-outward.
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Hira Usman, DPT, Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 21, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 5, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 5, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 29, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 8, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 9, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 9, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 8, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR&AHS/24/0482

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings